242 related articles for article (PubMed ID: 17992291)
1. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
[TBL] [Abstract][Full Text] [Related]
2. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
3. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
Scolaro C; Hartinger CG; Allardyce CS; Keppler BK; Dyson PJ
J Inorg Biochem; 2008 Sep; 102(9):1743-8. PubMed ID: 18582946
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
5. Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds.
Nazarov AA; Risse J; Ang WH; Schmitt F; Zava O; Ruggi A; Groessl M; Scopelitti R; Juillerat-Jeanneret L; Hartinger CG; Dyson PJ
Inorg Chem; 2012 Mar; 51(6):3633-9. PubMed ID: 22394115
[TBL] [Abstract][Full Text] [Related]
6. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
7. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
8. Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
Nowak-Sliwinska P; van Beijnum JR; Casini A; Nazarov AA; Wagnieres G; van den Bergh H; Dyson PJ; Griffioen AW
J Med Chem; 2011 Jun; 54(11):3895-902. PubMed ID: 21534534
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
10. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
[TBL] [Abstract][Full Text] [Related]
11. Dialkylamino cyclopentadienyl ruthenium(ii) complex-catalyzed alpha-alkylation of arylacetonitriles with primary alcohols.
Cheung HW; Li J; Zheng W; Zhou Z; Chiu YH; Lin Z; Lau CP
Dalton Trans; 2010 Jan; (1):265-74. PubMed ID: 20023959
[TBL] [Abstract][Full Text] [Related]
12. Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds.
Dorcier A; Hartinger CG; Scopelliti R; Fish RH; Keppler BK; Dyson PJ
J Inorg Biochem; 2008; 102(5-6):1066-76. PubMed ID: 18086499
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action.
Das S; Sinha S; Britto R; Somasundaram K; Samuelson AG
J Inorg Biochem; 2010 Feb; 104(2):93-104. PubMed ID: 19913918
[TBL] [Abstract][Full Text] [Related]
15. Heteroleptic arene ruthenium complexes based on meso-substituted dipyrrins: synthesis, structure, reactivity, and electrochemical studies.
Yadav M; Singh AK; Maiti B; Pandey DS
Inorg Chem; 2009 Aug; 48(16):7593-603. PubMed ID: 19610658
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium(II) and ruthenium(IV) complexes containing kappa1-P-, kappa2-P,O-, and kappa3-P,N,O-iminophosphorane-phosphine ligands Ph2PCH2P[=NP(=O)(OR)2]Ph2 (R = Et, Ph): synthesis, reactivity, theoretical studies, and catalytic activity in transfer hydrogenation of cyclohexanone.
Cadierno V; Crochet P; Díez J; García-Alvarez J; García-Garrido SE; Gimeno J; García-Granda S; Rodríguez MA
Inorg Chem; 2003 May; 42(10):3293-307. PubMed ID: 12739971
[TBL] [Abstract][Full Text] [Related]
17. Controlling the reactivity of ruthenium(II) arene complexes by tether ring-opening.
Pizarro AM; Melchart M; Habtemariam A; Salassa L; Fabbiani FP; Parsons S; Sadler PJ
Inorg Chem; 2010 Apr; 49(7):3310-9. PubMed ID: 20205442
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and intramolecular and interionic structural characterization of half-sandwich (arene)ruthenium(II) derivatives of bis(pyrazolyl)alkanes.
Marchetti F; Pettinari C; Pettinari R; Cerquetella A; Di Nicola C; Macchioni A; Zuccaccia D; Monari M; Piccinelli F
Inorg Chem; 2008 Dec; 47(24):11593-603. PubMed ID: 18998632
[TBL] [Abstract][Full Text] [Related]
19. In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C.
Ratanaphan A; Temboot P; Dyson PJ
Chem Biodivers; 2010 May; 7(5):1290-302. PubMed ID: 20491084
[TBL] [Abstract][Full Text] [Related]
20. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
